Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
12/01/20161:34PMBWThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Mylan NV Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Mylan N.V. (“Mylan” or the “Company”) (NASDAQ: MYL) securities between February 28, 2013 and October 7, 2016, inclusive (the “Class Period”). Mylan investors have until December 12, 2016 to... More...>>
12/01/20169:37AMPRNUSMylan's Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever
Mylan's Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2016 /PRNewswire/ -- Today, Mylan N.V. (NASDAQ, TASE: MYL) joins people worldwide in recognizing World AIDS Day. Observed every Dec. 1, the... More...>>
11/28/20167:30AMPRNUSMylan Signs Sub-license Agreement with the Medicines Patent Pool to Increase Access to Hepatitis C Treatment in Developing Co...
Mylan Signs Sub-license Agreement with the Medicines Patent Pool to Increase Access to Hepatitis C Treatment in Developing Countries PR Newswire HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
11/25/201611:34AMPRNUSSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Mylan N.V...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Mylan N.V. To Contact The Firm Before Lead Plaintiff Deadline PR Newswire NEW YORK, Nov. 25, 2016 NEW YORK, Nov. 25, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm... More...>>
11/18/201611:45PMBWDEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Lo...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Mylan N.V. (Nasdaq: MYL) (“Mylan” or the “Company”) securities during the... More...>>
11/18/201610:07PMBWMYLAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess ...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Mylan N.V. (NasdaqGS: MYL), if they purchased the Company’s securities... More...>>
11/09/20165:50PMDJNMylan Posts Loss, Hurt by Lower EpiPen Volumes, Charge Related to Settlement
Mylan NV swung to a quarterly loss as it booked a big charge related to a settlement with authorities on contentious pricing of its EpiPen, and revenue growth came in below expectations as volumes of the lifesaving auto-injector fell. Still, shares added 1.1% after hours to $39.35. Earlier in the day, the stock had joined... More...>>
11/09/20164:05PMPRNUSMylan Reports Third Quarter 2016 Results
Mylan Reports Third Quarter 2016 Results PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2016 HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and nine months ended September 30, 2016. Third Quarter 2016... More...>>
11/09/201610:30AMBWINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Mylan NV Investors Concerning Recent Reve...
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Mylan NV (“Mylan”) or the “Company”) (NASDAQ: MYL) concerning recent reports that the Company has unlawfully colluded with other pharmaceutical companies to fix generic drug prices. According to news reports United States prosecutors... More...>>
11/08/20167:30AMPRNUSMylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab
Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab Potential to be First Submission of a Proposed Biosimilar Trastuzumab in the U.S. Marks First U.S. Regulatory Submission through the Mylan/Biocon Collaboration and Important Step in Expanding Access to Biosimilars Worldwide PR Newswire HERTFORDSHIRE... More...>>
11/04/201610:07PMPRNUSMYLAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS ...
MYLAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mylan N.V. - MYL PR Newswire NEW ORLEANS, Nov. 4, 2016 NEW ORLEANS, Nov. 4, 2016 /PRNewswire/ -- Kahn Swick & Foti... More...>>
11/03/20166:51PMBWGlancy Prongay & Murray LLP Commences Investigation on Behalf of Mylan NV Investors Concerning Recent Revelations Regarding A...
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Mylan NV (“Mylan”) or the “Company”) (NASDAQ: MYL) investors concerning recent reports that the Company has unlawfully colluded with other pharmaceutical companies to fix generic drug prices. According to news reports United States... More...>>
11/03/20166:10PMDJNGeneric-Drug Makers' Shares Drop on Report of Possible Probe
Shares of generic-drug makers declined Thursday on a report that U.S. prosecutors were conducting a criminal investigation of possible price collusion in the industry. The report by Bloomberg News on Thursday sent shares of Endo International PLC down 20%, while Teva Pharmaceutical Industries Ltd. declined 9.5%, and Mylan... More...>>
11/03/20164:08PMDJNDOJ Looking Into Possible Price Collusion in Generic Drug Sector -Bloomberg
A Justice Department probe of possible price collusion by generic drug companies could lead to criminal charges by the end of the year, Bloomberg News reported Thursday. The investigation spans more than a dozen companies, Bloomberg reported, citing people familiar with the matter. Shares of several generic drug makers... More...>>
11/03/20169:15AMPRNUSMylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency
Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency PR Newswire HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 3, 2016 HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 3, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and... More...>>
11/02/20165:29PMBWGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Mylan N.V. Investors & Encourages Inve...
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Mylan N.V. (“Mylan”) or the “Company”) (NASDAQ: MYL) securities between February 21, 2012 and October 5, 2016, inclusive (the “Class Period”). Mylan investors have until December... More...>>
11/02/20168:00AMPRNUSMomenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept) -- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio -- PR Newswire CAMBRIDGE, Mass. and HERTFORDSHIRE, England and PITTSBURGH, Nov. 2, 2016... More...>>
10/27/20168:10AMDJNMylan Executives Unlikely to Lose Pay Over EpiPen Issue
Executives of EpiPen maker Mylan NV are unlikely to suffer a reduction in their pay from the company's recent $465 million settlement of allegations that it improperly overcharged Medicaid for the lifesaving drug. That is because Mylan historically has calculated executive pay using a nonstandard measure called "adjusted... More...>>
10/26/20161:25PMPRNUSMylan Launches First Generics of Benicar® and Benicar HCT® Tablets
Mylan Launches First Generics of Benicar® and Benicar HCT® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Oct. 26, 2016 HERTFORDSHIRE, England and PITTSBURGH, Oct. 26, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launches of the first generic versions of Daiichi Sankyo's Benicar®... More...>>
10/26/20161:02PMPRNUSEpiPen Maker Mylan Hit With Class-Action Lawsuit
EpiPen Maker Mylan Hit With Class-Action Lawsuit Lawsuit seeks damages for Mylan's unconscionable sales tactics PR Newswire HOUSTON, Oct. 26, 2016 HOUSTON, Oct. 26, 2016 /PRNewswire/ -- A class-action lawsuit filed against pharmaceutical giant Mylan Inc. (NASDAQ: MYL) seeks damages for consumers victimized by the company's... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V:us D:20161203 23:48:16